Federal Register Final rule: FDA is amending the animal drug regulations to reflect approval of a Boehringer Ingelheim Vetmedica original new animal drug application that provides for veterinary prescription use of an injectable suspension of protamine zinc recombinant human insulin for reducing hyperglycemia and hyperglycemia-associated clinical signs in cats with diabetes mellitus. To view this final rule, click here.
